目的探讨乙肝隐匿型感染(occult infection of HBV)在隐源性肝病中的感染率。方法采用PCR技术从健康献血人员与HBsAg阴性的隐源性肝病患者(包括肝硬化、肝癌、丙肝与病因不清肝炎)血清中检测HBV X DNA,统计并分析HBV在各组中的感染率。...目的探讨乙肝隐匿型感染(occult infection of HBV)在隐源性肝病中的感染率。方法采用PCR技术从健康献血人员与HBsAg阴性的隐源性肝病患者(包括肝硬化、肝癌、丙肝与病因不清肝炎)血清中检测HBV X DNA,统计并分析HBV在各组中的感染率。结果隐匿型HBV在健康人群中的感染率为5%,而在隐源性肝硬化、肝癌、丙肝与病因不清肝炎中的感染率分别为30%、20%、32%、7.4%。与健康人群相比,隐源性肝硬化、肝癌与丙肝患者的HBV感染率显著增加、但病因不清肝炎患者HBV感染率却无显著差异。研究还发现,肝硬化与肝癌患者的性别/HBV抗体的检出与HBV感染率的关系不大,但丙肝患者其HBV抗体的检出与HBV感染率有密切的联系。结论本研究小范围内统计了隐匿型HBV在隐源性肝病中的感染率,并证实HBV隐匿型感染在隐源性肝硬化、肝癌患者中与性别、HBV抗体检出没有关系,而在丙肝患者中其与乙肝血清抗体的检出相关。展开更多
Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide,with 75% of those affected distributed in the Asia-Pacific region.Approximately one million HBV-infected patients die of liver cirrhosis ...Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide,with 75% of those affected distributed in the Asia-Pacific region.Approximately one million HBV-infected patients die of liver cirrhosis and hepatocellular carcinoma (HCC) each year.If left untreated,6-20% of chronic hepatitis B (CrHB) patients will develop cirrhosis over five years.The cumulative incidence of HBV-related cirrhosis,disease progression,and prognosis are closely associated with serum HBV DNA levels.Antiviral therapy in HBV-related cirrhosis has been documented by several long-term cohort studies to decrease disease progression to hepatic decompensation and HCC.The approval and availability of oral antiviral agents with better safety profiles has greatly improved the prognosis for HBV-related cirrhosis.Here,we discuss the significance of antiviral therapy for HBV-related cirrhosis and the management of HBV-related diseases in the future.展开更多
文摘目的探讨乙肝隐匿型感染(occult infection of HBV)在隐源性肝病中的感染率。方法采用PCR技术从健康献血人员与HBsAg阴性的隐源性肝病患者(包括肝硬化、肝癌、丙肝与病因不清肝炎)血清中检测HBV X DNA,统计并分析HBV在各组中的感染率。结果隐匿型HBV在健康人群中的感染率为5%,而在隐源性肝硬化、肝癌、丙肝与病因不清肝炎中的感染率分别为30%、20%、32%、7.4%。与健康人群相比,隐源性肝硬化、肝癌与丙肝患者的HBV感染率显著增加、但病因不清肝炎患者HBV感染率却无显著差异。研究还发现,肝硬化与肝癌患者的性别/HBV抗体的检出与HBV感染率的关系不大,但丙肝患者其HBV抗体的检出与HBV感染率有密切的联系。结论本研究小范围内统计了隐匿型HBV在隐源性肝病中的感染率,并证实HBV隐匿型感染在隐源性肝硬化、肝癌患者中与性别、HBV抗体检出没有关系,而在丙肝患者中其与乙肝血清抗体的检出相关。
基金the National Key Technologies Research and Development Program of China during the 11th/12th Five-year Plan Period (no.2008ZX1002-006,2012ZX10002007-001-040 and 2013ZX10002004-002-003)
文摘Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide,with 75% of those affected distributed in the Asia-Pacific region.Approximately one million HBV-infected patients die of liver cirrhosis and hepatocellular carcinoma (HCC) each year.If left untreated,6-20% of chronic hepatitis B (CrHB) patients will develop cirrhosis over five years.The cumulative incidence of HBV-related cirrhosis,disease progression,and prognosis are closely associated with serum HBV DNA levels.Antiviral therapy in HBV-related cirrhosis has been documented by several long-term cohort studies to decrease disease progression to hepatic decompensation and HCC.The approval and availability of oral antiviral agents with better safety profiles has greatly improved the prognosis for HBV-related cirrhosis.Here,we discuss the significance of antiviral therapy for HBV-related cirrhosis and the management of HBV-related diseases in the future.
